HALOZYME THERAPEUTICS INC Contracts & Agreements

Form of Restricted Unit Agreement (2021 plan updated June 2024) (Filed With SEC on August 6, 2024)

Severance Policy (Filed With SEC on February 20, 2024)

Form of Stock Option Agreement (2021 Plan updated May 2023) (Filed With SEC on August 8, 2023)

Form of Restricted Stock Unit Agreement (2021 Plan updated May 2023) (Filed With SEC on August 8, 2023)

Form of Restricted Unit Agreement (2021 Plan Sell-to-Cover updated May 2023) (Filed With SEC on August 8, 2023)

Form of Director Stock Option Agreement (2021 Plan) (Filed With SEC on August 8, 2023)

Letter Agreement Amending Exercise Period for Employee Option (Filed With SEC on August 8, 2023)

Amendment No. 2 to the Credit Agreement (Filed With SEC on May 9, 2023)

Severance Policy (Filed With SEC on November 8, 2022)

Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on November 8, 2022)

Amendment No. 1 to the Credit Agreement (Filed With SEC on August 19, 2022)

Indenture, dated August 18, 2022 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (Filed With SEC on August 18, 2022)

Form of Capped Call Confirmation (Filed With SEC on August 18, 2022)

Credit Agreement, dated as of May 24, 2022, by and among Halozyme Therapeutics, Inc., the Guarantors, Bank of America N.A. and each of those additional Lenders that are a party to... (Filed With SEC on May 24, 2022)

Security Agreement, dated as of May 24, 2022, by and among Halozyme Therapeutics, Inc., the Guarantors and Bank of America N.A (Filed With SEC on May 24, 2022)

Agreement for Assignment and Assumption of Lease, Del Mar Corporate Centre I Office Lease and First Amendment to Office Lease (Filed With SEC on May 10, 2022)

Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme Therapeutics, Inc., Atlas Merger Sub, Inc. and Antares Pharma, Inc (Filed With SEC on April 13, 2022)

Description of Securities (Filed With SEC on February 22, 2022)

Halozyme Therapeutics, Inc. Non Qualified Deferred Compensation Plan Adoption Agreement (Filed With SEC on February 22, 2022)

Halozyme Therapeutics, Inc Directors Deferred Equity Compensation Plan (Filed With SEC on February 22, 2022)

Form of Restricted Stock Units Agreement for Irish Participants (2021 Stock Plan) (Filed With SEC on August 9, 2021)

Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on May 5, 2021)

Halozyme Therapeutics, Inc. 2021 Stock Plan (Filed With SEC on May 5, 2021)

Form of Stock Option Agreement (2021 Stock Plan) (Filed With SEC on May 5, 2021)

Form of Restricted Stock Units Agreement for Officers (2021 Stock Plan) (Filed With SEC on May 5, 2021)

Form of Restricted Stock Units Agreement (2021 Stock Plan) (Filed With SEC on May 5, 2021)

Form of Restricted Stock Award Agreement (2021 Stock Plan) (Filed With SEC on May 5, 2021)

Form of Performance Stock Units Agreement (2021 Stock Plan) (Filed With SEC on May 5, 2021)

Form of Director Restricted Stock Units Agreement (2021 Stock Plan) (Filed With SEC on May 5, 2021)

Indenture, dated March 1, 2021 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (Filed With SEC on March 1, 2021)

Form of Note, dated March 1, 2021 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (Filed With SEC on March 1, 2021)

Form of PSU Agreement (Filed With SEC on February 23, 2021)

Form of Performance Stock Units Agreement Under the Halozyme Therapeutics, Inc 2011 Stock Plan (Filed With SEC on August 10, 2020)

Description of Securities (Filed With SEC on February 24, 2020)

Form of Note, dated November 18, 2019 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A, as trustee (Filed With SEC on November 18, 2019)

Indenture, dated November 18, 2019 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A, as trustee (Filed With SEC on November 18, 2019)

Third Amendment to Loan and Security Agreement between Oxford, SVB and Registrant, dated June 14, 2019 (Filed With SEC on August 6, 2019)

Halozyme Therapeutics, Inc. Severance Policy (Filed With SEC on December 13, 2018)

Halozyme Therapeutics, Inc. Severance Policy (Filed With SEC on November 6, 2018)

Second Amendment to Amended and Restated Lease (11388 Sorrento Valley Road), dated March 23, 2018 (Filed With SEC on May 10, 2018)

Second Amendment to Lease (11404 and 11408 Sorrento Valley Road), dated March 23, 2018 (Filed With SEC on May 10, 2018)

Halozyme Therapeutics, Inc. 2011 Stock Plan, as proposed to be amended (Filed With SEC on April 6, 2018)

Consent, Release, and Second Amendment to Loan and Security Agreement, dated November 21, 2017 (Filed With SEC on February 20, 2018)

FIRST AMENDMENT TO AMENDED AND RESTATED LEASE (Filed With SEC on July 5, 2017)

FIRST AMENDMENT TO LEASE (Filed With SEC on July 5, 2017)

SECOND MODIFICATION TO LEASE DATED OCTOBER 24, 2012 BY AND BETWEEN CAL-SORRENTO, LTD., A CALIFORNIA LIMITED PARTNERSHIP AS LESSOR AND HALOZYME THERAPEUTICS, INC., A DELAWARE... (Filed With SEC on July 5, 2017)

HALOZYME THERAPEUTICS, INC. 10,000,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement (Filed With SEC on May 19, 2017)

HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK UNITS AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2011 STOCK PLAN (Filed With SEC on February 28, 2017)

CONSENT, RELEASE, AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 28, 2017)

LOAN AND SECURITY AGREEMENT (Filed With SEC on August 9, 2016)

CONSENT, RELEASE AND THIRD AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on February 29, 2016)

CREDIT AGREEMENT Dated as of December , 2015 (Filed With SEC on February 29, 2016)

AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (Filed With SEC on November 9, 2015)

HALOZYME THERAPEUTICS, INC. STOCK OPTION AGREEMENT (Filed With SEC on November 9, 2015)

HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK AWARD AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2011 STOCK PLAN (Filed With SEC on November 9, 2015)

HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK UNITS AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2011 STOCK PLAN (Filed With SEC on November 9, 2015)

HALOZYME THERAPEUTICS, INC. 2011 STOCK PLAN (as amended through May 6, 2015) (Filed With SEC on August 10, 2015)

HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK UNITS AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2011 STOCK PLAN (Filed With SEC on August 10, 2015)

HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK AWARD AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2011 STOCK PLAN (Filed With SEC on August 10, 2015)

SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT AND FIRST AMENDMENT TO DISBURSEMENT LETTER (Filed With SEC on March 2, 2015)

CONSENT AND FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on August 11, 2014)

CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS (Filed With SEC on May 12, 2014)

FORM CEO CHANGE IN CONTROL AGREEMENT (Filed With SEC on February 28, 2014)

AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on February 28, 2014)

HALOZYMETHERAPEUTICS, INC. 7,692,307 Shares of Common Stock, par value $0.001 per share Underwriting Agreement (Filed With SEC on February 5, 2014)

FIRST MODIFICATION TO LEASE DATED OCTOBER 24, 2012 BY AND BETWEEN CAL-SORRENTO, LTD., A CALIFORNIA LIMITED PARTNERSHIP AS LESSOR AND HALOZYME THERAPEUTICS, INC., A DELAWARE... (Filed With SEC on May 8, 2013)

AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (Filed With SEC on March 1, 2013)

CHANGE IN CONTROL AGREEMENT (Filed With SEC on March 1, 2013)

AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE -- GROSS (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS) (Filed With SEC on March 1, 2013)

6,800,000 Shares HALOZYME THERAPEUTICS, INC. Common Stock ($0.001 par value) UNDERWRITING AGREEMENT (Filed With SEC on February 10, 2012)

Entry into Material Definitive Agreements (Filed With SEC on June 16, 2011)

Halozyme Therapeutics, Inc. 2011 Stock Plan (Filed With SEC on May 6, 2011)

HALOZYME THERAPEUTICS, INC. STOCK OPTION AGREEMENT (Filed With SEC on May 6, 2011)

Halozyme Therapeutics, Inc. Restricted Stock Units Agreement under the Halozyme Therapeutics, Inc. 2011 Stock Plan (Filed With SEC on May 6, 2011)

Halozyme Therapeutics, Inc. Restricted Stock Award Agreement under the Halozyme Therapeutics, Inc. 2011 Stock Plan (Filed With SEC on May 6, 2011)

Develop our own proprietary products based on our PH20 enzyme and other new molecular entities (Filed With SEC on March 11, 2011)

TERMINATION AGREEMENT (Filed With SEC on January 10, 2011)

8,300,000 Shares HALOZYME THERAPEUTICS, INC. Common Stock ($0.001 par value) UNDERWRITING AGREEMENT (Filed With SEC on September 9, 2010)

Financial Statements (Filed With SEC on August 7, 2009)

Exhibit No (Filed With SEC on June 23, 2009)

Current assets (Filed With SEC on November 7, 2008)

Cash and cash equivalents (Filed With SEC on May 9, 2008)

Develop our own proprietary products based on our PH20 enzyme and other new molecular entities (Filed With SEC on March 14, 2008)

Current assets (Filed With SEC on August 8, 2006)

HALOZYME THERAPEUTICS, INC. (Filed With SEC on May 8, 2006)

Exhibit No (Filed With SEC on March 30, 2005)

Exhibit No (Filed With SEC on February 22, 2005)

Securities Purchase Agreement dated as of October 12, 2004 (Filed With SEC on October 15, 2004)

Category

Industry

Companies

Contracts

HALOZYME THERAPEUTICS INC Contracts & Agreements